Compare IQV & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IQV | KVUE |
|---|---|---|
| Founded | 1982 | 2022 |
| Country | United States | United States |
| Employees | 93000 | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Specialty Chemicals |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.1B | 32.9B |
| IPO Year | 2013 | 2023 |
| Metric | IQV | KVUE |
|---|---|---|
| Price | $238.70 | $19.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 11 |
| Target Price | ★ $227.13 | $19.45 |
| AVG Volume (30 Days) | 1.4M | ★ 19.2M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 4.82% |
| EPS Growth | 4.67 | ★ 40.74 |
| EPS | ★ 1.61 | 0.48 |
| Revenue | $9,739,000,000.00 | ★ $15,124,000,000.00 |
| Revenue This Year | $6.77 | $4.85 |
| Revenue Next Year | $5.89 | $2.63 |
| P/E Ratio | $144.37 | ★ $39.80 |
| Revenue Growth | ★ 41.60 | N/A |
| 52 Week Low | $154.50 | $14.02 |
| 52 Week High | $251.36 | $21.96 |
| Indicator | IQV | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 62.34 | 49.78 |
| Support Level | $218.57 | $18.68 |
| Resistance Level | $247.52 | $20.09 |
| Average True Range (ATR) | 7.83 | 0.47 |
| MACD | 0.63 | -0.04 |
| Stochastic Oscillator | 64.79 | 30.79 |
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.